Analysis of the drug treatment in patients with stable coronary artery disease before and after surgical myocardial revascularization

О.J. Zharinov, О.А. Yepanchintseva, К.O. Mikhaliev, I.V. Shklianka

References  

1. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2016;37:2999-3058. doi: 10.1093/eurheartj/ehr158.
2. Hillis LD, Smith PK, Anderson JL, Bittl JA. et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2012;143:4-34. doi: 10.1016/j.jtcvs.2011.10.015.
3. Huffmann MD, Xavier D, Perel P. Uses of polypills for cardiovascular disease and evidence to date. Lancet. 2017;389:1055-1065. doi: 10.1016/S0140-6736(17)30553-6.
4. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452-458.
5. Kulik A, Ruel M, Jneid H. Secondary prevention after coronary artery bypass graft surgery. A Scientific Statement from the American Heart Association. Circulation. 2015;10:927-964.
6. McKavanagh P, Yanagawa B, Zawadowski G, Cheema A. Management and prevention of saphenous vein graft failure: a review. Cardiology and Therapy. 2017;6(2):203-223. doi: 10.1007/s40119-017-0094-6.
7. Montalescot G, Sechtem U, Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease. The task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949-3003.
8. Neumann F-J, Sousa-Uva M, Ahlsson A. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2018;00:1-96. doi: 10.1093/eurheartj/ehy394.
9. Philip F, Blackstone E, Kapadia SR. Impact of statins and beta-blocker therapy on mortality after coronary artery bypass graft surgery. Cardiovasc Diagn Ther. 2015;5(1):8-16.
10. Pinho-Gomes AC, Azevedo L, Ahn JM. et al. Compliance with guideline-directed medical therapy in contemporary coronary revascularization trials. J Am Coll Cardiol. 2018;71:591-602. doi: 10.1016/j.jacc.2017.11.068.
11. Sousa-Uva M, Storey R, Huber K. et al, on behalf of ESC Working Group on Cardiovascular Surgery and ESC Working Group on Thrombosis. Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. Eur Heart J. 2014;35:1510-1514.
12. Valgimigli M, Bueno H, Byrne RA. et al. The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213-260. doi: 10.1093/eurheartj/ehx419.
13. Windecker S, Kolh P, Alfonso F. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014;46(4):517-592. doi: 10.1093/eurheartj/ehu278.